DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Thursday. The brokerage issued a hold rating on the stock.

DBVT has been the topic of a number of other research reports. HC Wainwright upped their price objective on DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $0.59 on Thursday. The firm has a market cap of $56.92 million, a price-to-earnings ratio of -0.66 and a beta of 0.66. The firm has a 50 day simple moving average of $0.72 and a 200-day simple moving average of $0.88. DBV Technologies has a one year low of $0.50 and a one year high of $2.14.

Shares of DBV Technologies are going to reverse split before the market opens on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its holdings in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies makes up about 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.